Transplantation Clinical Trial
— PREDICTOfficial title:
Plerixafor and G−CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non−Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) − Safety Study in a General Autologous Transplant Population
This is a research study intended to further investigate the safety and efficacy of plerixafor in patients with NHL, HD, or MM. Patients who have previously failed stem cell mobilisation attempts or who have previously received more than one autologous or any allogeneic stem cell transplant are not eligible.
Status | Completed |
Enrollment | 118 |
Est. completion date | November 2010 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of MM, NHL, or HD in partial response (PR) or complete response (CR) - Eligible and planned for an autologous haematopoietic stem cell transplantation - Written informed consent - At least 18 years of age (inclusive) - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 - White blood cell (WBC) count =2.5 x 10^9/L - Absolute neutrophil count (ANC) =1.5 x 10^9 /L - Platelet count =100 x 10^9/L - Serum creatinine =2.2 mg/dL - Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT), and total bilirubin <2.5 x upper limit of normal (ULN) - Adequate cardiac, renal, and pulmonary function sufficient to undergo apheresis and transplantation, i.e., eligible by institutional standards for autologous stem cell transplant - All patients must agree to use a highly effective method of contraception whilst on study treatment and for at least 3 months following plerixafor treatment (including both female patients of child-bearing potential and male patients with partners of child-bearing potential). Effective birth control includes: a) birth control pills, depot progesterone, or an intrauterine device plus one barrier method, or b) two barrier methods. Effective barrier methods are: male and female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). For patients using a hormonal contraceptive method, information about any interaction of plerixafor with hormonal contraceptives is not known. Exclusion Criteria: - History of any acute or chronic leukaemia (including myelodysplastic syndrome) - Prior allogeneic transplantation or more than one prior autologous transplantation - Failed previous CD34+ cell collection attempts (either due to insufficient yield in apheresis product, or ineligible for apheresis because of inadequate mobilisation of CD34+ cells into peripheral blood) - Less than 4 weeks since last anti-cancer therapy (including chemotherapy, biologic/immunologic, radiation) or less than 6 weeks if prior therapy with nitrosourea or mitomycin (for therapies with long-acting agents, a treatment-free interval of at least 2 half-lives should be considered) with the exception of ; Treatment with thalidomide, dexamethasone, lenalidomide (Revlimid®), and/or bortezomib (Velcade®) which is allowed up to 7 days prior to the first dose of G-CSF. - Bone marrow involvement >20% assessed based on the most recent bone marrow aspirate or biopsy - Treated with G-CSF or other cytokine within 14 days prior to the first dose of G-CSF for mobilisation - Known to be human immunodeficiency virus (HIV) positive - Active hepatitis B or hepatitis C - Acute infection (febrile, i.e., temperature >38°C) within 24 hours prior to dosing or antibiotic therapy within 7 days prior to the first dose of G-CSF - Hypercalcaemia as evidenced by >1 mg/dL above ULN - Previously received investigational therapy within 4 weeks of enrolling in this protocol or currently enrolled in another investigational protocol during the mobilisation phase - Central nervous system involvement including brain metastases or leptomeningeal disease - Pregnant or nursing women - Electrocardiogram (ECG) or study result (exercise study, scan) indicative of cardiac ischaemia or a history of clinically significant rhythm disturbance (arrhythmias), or other conduction abnormality in the last year that in the opinion of the Investigator warrants exclusion of the subject from the trial. - Co-morbid condition(s), which in the opinion of the Investigator, renders the patient at high risk from treatment complications or impairs their ability to comply with the study treatment and protocol |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Hôpital du Haut Lévêque | Bordeaux | |
France | Hôpital Lyon Sud | Lyon | |
France | Institut Paoli Calmettes | Marseille | |
France | CHU Hotel-Dieu Université de Nantes | Nantes | |
France | Hôpital Saint-Louis | Paris | |
France | Institut Gustave Roussy | Villejuif | |
Germany | Charité - Campus Benjamin Franklin | Berlin | |
Germany | Klinikum der Universität zu Köln | Cologne | |
Germany | Universitätsklinikum Carl Gustav Carus | Dresden | |
Germany | Universitätsklinikum Heidelberg | Heidelberg | |
Germany | Klinikum Nürnberg Nord | Nürnberg | |
Germany | Universitätsklinik Würzburg | Würzburg | |
Italy | L. & A. Seragnoli, University of Bologna | Bologna | |
Italy | Ospedale Ferrarotto | Catania | |
Italy | Azienda Ospedaliera S. Martino | Genova | |
Netherlands | VU Medisch Centrum | Amsterdam | |
Spain | Hospital Santa Creu y Sant Pau | Barcelona | |
Spain | Hospital Carlos-Haya | Malaga | |
Spain | Hospital Universitario de Salamanca | Salamanca | |
Spain | Hospital la Fe | Valencia | |
Sweden | Karolinska Universitetssjukhuset Huddinge | Stockholm | |
Sweden | Akademiska Sjukhuset | Uppsala | |
United Kingdom | Gartnavel Hospital | Glasgow | |
United Kingdom | St James's University Hospital | Leeds | |
United Kingdom | King's college Hospital | London | |
United Kingdom | Nottingham University NHS Trust | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplant | 24 months | Yes | |
Secondary | To assess efficacy of plerixafor and granulocyte-colony stimulating factor (G-CSF) as a mobilisation regimen as measured by the number of CD34+ cells collected in each apheresis session | After each dose of plerixafor | No | |
Secondary | To assess the clinical effectiveness of plerixafor and G-CSF mobilised stem cells by examining haematopoietic cell engraftment and graft status | After transplantation | No | |
Secondary | To examine the influence of CD34+ cell dose infused on time to engraftment, engraftment and graft status | After transplantation | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00778856 -
Hand Transplantation for the Reconstruction of Below the Elbow Amputations
|
N/A | |
Active, not recruiting |
NCT00166842 -
Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
|
Phase 4 | |
Recruiting |
NCT04257747 -
Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI
|
N/A | |
Completed |
NCT02560909 -
Adjuvanted Influenza Vaccine in Stem Cell Transplant
|
Phase 4 | |
Active, not recruiting |
NCT01687192 -
Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.
|
Phase 2 | |
Completed |
NCT00951977 -
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
|
N/A | |
Completed |
NCT00384137 -
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients
|
Phase 3 | |
Completed |
NCT00384202 -
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients
|
Phase 3 | |
Completed |
NCT00235664 -
Prospective Study of Drug Resistant Pathogens Among Liver, Intestinal and Multivisceral Transplant Recipients
|
N/A | |
Completed |
NCT03533049 -
mHealth Family Self-Management
|
N/A | |
Completed |
NCT02826213 -
Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient
|
||
Completed |
NCT00170170 -
Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation
|
N/A | |
Recruiting |
NCT06367244 -
Transplant Wellness Program
|
N/A | |
Recruiting |
NCT06166186 -
Effect of Intraoperative Music on Inflammatory Response in Donor Hepatectomy
|
N/A | |
Recruiting |
NCT00493194 -
Fibrosis in Renal Allografts
|
Phase 4 | |
Completed |
NCT00297310 -
Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation
|
Phase 4 | |
Completed |
NCT01019811 -
Innervated Sensory Cross-Finger Flap
|
N/A | |
Completed |
NCT04376775 -
Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation
|
||
Active, not recruiting |
NCT00166816 -
The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients
|
Phase 4 | |
Recruiting |
NCT03920735 -
Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
|